End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43 SEK | -0.92% | +1.90% | +28.74% |
Apr. 22 | EQL Pharma AB Announces Mellozzan Launched in Germany and Austria | CI |
Feb. 13 | EQL Pharma AB Provides Sales Guidance for the Year 2023/24 | CI |
Sales 2024 * | 363M 33.36M | Sales 2025 * | 425M 39.03M | Capitalization | 1.25B 115M |
---|---|---|---|---|---|
Net income 2024 * | 60M 5.51M | Net income 2025 * | 76M 6.98M | EV / Sales 2024 * | 3.56 x |
Net Debt 2024 * | 41M 3.77M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.94 x |
P/E ratio 2024 * |
20.8
x | P/E ratio 2025 * |
16.3
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
1 day | -0.92% | ||
1 week | +1.90% | ||
Current month | +1.65% | ||
1 month | +9.14% | ||
3 months | +20.45% | ||
6 months | +54.12% | ||
Current year | +28.74% |
Managers | Title | Age | Since |
---|---|---|---|
Axel Schörling
CEO | Chief Executive Officer | 38 | 18-01-31 |
Founder | 59 | 05-12-31 | |
Anna Jönsson
DFI | Director of Finance/CFO | 40 | 21-12-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 59 | 05-12-31 | |
Director/Board Member | 63 | 14-12-31 | |
Director/Board Member | 51 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 43 | -0.92% | 2,142 |
24-04-24 | 43.4 | -0.23% | 4,478 |
24-04-23 | 43.5 | +2.35% | 12,185 |
24-04-22 | 42.5 | -0.47% | 9,771 |
24-04-19 | 42.7 | +1.18% | 7,394 |
End-of-day quote NORDIC GROWTH MARKET, April 24, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+28.74% | 115M | |
-32.59% | 15.18B | |
-31.97% | 10.1B | |
+9.54% | 6.12B | |
-11.41% | 5.97B | |
-30.42% | 5.65B | |
-0.88% | 4.71B | |
+51.58% | 4.26B | |
-12.22% | 3.58B | |
-16.75% | 3.26B |
- Stock Market
- Equities
- EQL Stock